γ-Secretase as a Therapeutic Target for Treatment of Alzheimers Disease

Author(s): Taisuke Tomita, Takeshi Iwatsubo.

Journal Name: Current Pharmaceutical Design

Volume 12 , Issue 6 , 2006

Submit Manuscript
Submit Proposal

Abstract:

Alzheimers disease (AD) is the most common cause of dementia with aging, that is pathologically characterized by senile plaques that contain amyloid-b peptides (Aβ) and neurofibrillary tangles comprised of phosphorylated tau. Genetic and biological studies provide evidence that the production and deposition of Aβ contribute to the etiology of AD. g-Secretase is the pivotal enzyme in generating the C terminus of Aβ, that determines its aggregability and propensity for deposition. Drugs that regulate the production of Aβ by inhibiting g-secretase activity could provide an effective therapeutics for AD, although recent studies suggest that g-secretase plays important roles in novel signaling pathways that play essential roles in embryonic development. This review focuses on recent progresses in the g-secretase biology that shed substantial light on the proteolytic mechanism, regulation and composition of this unusual enzyme. Moreover, we review the recent development of inhibitors and provide a direction for the effective treatment of AD through inhibition of g-secretase activity.

Keywords: Alzheimer's disease, amyloid, γ-secretase, presenilin, aspartic protease, intramembrane proteolysis, protease inhibitor

Rights & PermissionsPrintExport Cite as


Article Details

VOLUME: 12
ISSUE: 6
Year: 2006
Page: [661 - 670]
Pages: 10
DOI: 10.2174/138161206775474206
Price: $58

Article Metrics

PDF: 1